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Abstract Severe Traumatic Brain Injury (TBI) remains a major cause of death and
disability afﬂicting mostly young adult males and elderly people, resulting in high
economic costs to society. Therapeutic approaches focus on reducing the risk on
secondary brain injury. Speciﬁc ethical issues pertaining in clinical testing of
pharmacological neuroprotective agents in TBI include the emergency nature of the
research, the incapacity of the patients to informed consent before inclusion, short
therapeutic time windows, and a risk-beneﬁt ratio based on concept that in relation
to the severity of the trauma, signiﬁcant adverse side effects may be acceptable for
possible beneﬁcial treatments. Randomized controlled phase III trials investigating
the safety and efﬁcacy of agents in TBI with promising beneﬁt, conducted in acute
emergency situations with short therapeutic time windows, should allow randomi-
zation under deferred consent or waiver of consent. Making progress in knowledge
of treatment in acute neurological and other intensive care conditions is only pos-
sible if national regulations and legislations allow waiver of consent or deferred
consent for clinical trials.
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Severe Traumatic Brain Injury (TBI) remains a major cause of death and disability
afﬂicting mostly young adult males and elderly people, resulting in high economic
costs to society [1]. Road trafﬁc accidents, domestic and work-related falls and
assaults are the main causes of TBI in Europe. The fatality rate for severe TBI is
about 30% and a signiﬁcant disability in 35–40% in unselected series. The primary
injury initiates a complex sequence of events resulting in secondary brain damage,
which can be exacerbated by systemic insults, such as hypotension and hypoxia.
Therapeutic approaches focus on reducing the risk on secondary brain injury.
Pharmacological neuroprotective agents aim to limit secondary brain damage after
the primary acute injury and aim to improve overall outcome. Various neuropro-
tective agents, mainly targeting speciﬁc pathophysiologic mechanisms, have been
tested in TBI, but convincing beneﬁt has not been shown [2]. These data signify an
ethical imperative to develop and test new therapeutic strategies and neuroprotec-
tive pharmacological agents in the ﬁeld of TBI.
The most important ethical issues pertaining to clinical pharmacological trials in
severe TBI are:
1. emergency nature of the research
2. incapacity of the patients to consent
3. short therapeutic time windows
4. risk/beneﬁt ratio based on the concept that in relation to the seriousness of the
injury, signiﬁcant adverse side effects may be acceptable for treatments with
possible beneﬁt.
The importance of implications of these issues is not fully recognized outside,
and even within, the expert ﬁeld of treatment of severe TBI.
Therapeutic trials to evaluate the efﬁcacy and safety of pharmacological agents
are subject to the ethical and juridical principles of Good Clinical Practice, national
legislation and European and international regulations. The guiding ethical
principles underlying these investigations of treatment are respect for autonomy
of the subjects, protection against discomfort, harm, risk and exploitation and the
prospect of beneﬁt. The prospect of beneﬁt is almost always complicated by the
equipoise underpinning the statistical null hypothesis of pharmacological trials:
the hope that an individual patient will beneﬁt, but that this is not more certain than
the chance of non beneﬁt.
Countries in the European Union are amending legislation to comply with the
European Union Directive 2001/20/EC [3]. In this European legislation, emergency
research under deferred or waiver of consent is however not permitted. This will
impede or even obviate emergency research phase III trials in TBI in the European
countries [4–6].
The European Clinical trial Directive 2001/20/EC was originally aimed as a
European-wide harmonization of the provisions concerning clinical pharmacolog-
ical trials, with a focus at the facilitation of multi-national clinical research. Since
the publication in 2001, several articles drew attention to the serious threat to the
development of evidence-based critical care and emergency research within the
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informed written consent before subjects can be recruited to clinical trials of
medicinal products [7–19].
The Directive made no direct exception for emergency and critical care
situations, and therefore threatened to prevent all emergency trials involving
patients with acute catastrophic illness causing loss of decision-making capacity and
facing (very) short therapeutic time windows, such as severe shock, circulatory
arrest, acute myocardial infarction, severe stroke and other acute neurological
conditions, and moderate and severe traumatic brain injury.
Implementation by all EU countries was required by May 2004. The wording of
the Directive permitted some ﬂexibility so that variations were expected that might
impact on emergency research [20]. Lemaire et al. [9] have described the variations
in national legislative responses to the Directive within Europe; they called on
legislators to permit waivers of informed consent for emergency and critical care
research, to clarify terms and deﬁnitions, and to remove the artiﬁcial distinction
between interventional and observational research. Concerning practice in The
Netherlands, the requirements as described in the Directive have been transposed
into the revision of the Medical Research in Human Subjects Act (WMO) and
Medicine law (WOG) [21]. The amended WMO will change the rules governing
drugs studies in The Netherlands. There will be little, if any, change to non-drug
research. The Dutch Parliament has accepted the amended WMO for the
implementation (amended WMO) at November 22, 2005 and the revised Act
became effective in The Netherlands on March 1, 2006.
The Directive was conceived in part to ensure that participants enrolled in
research projects are given adequate information about the nature of the trials and
the associated risks. Legislation to protect the interests of patients was necessary
and timely. The research community welcomed most of the Articles in the
Directive; they offer guidance and will help to maintain conﬁdence in the probity of
medical research. Unfortunately, however, neither those responsible for the
Directive, nor many who drafted enabling legislation within Member States,
considered the special problems relating to research in emergency nor critical care
situations, where consent cannot be obtained from subjects and where the need for
emergency treatment does not allow time for contact with relatives or other legal
representatives. Moreover, in the United States, in 1996, the FDA had published a
waiver of informed consent for certain types of emergency and critical care research
after earlier strict provisions had brought to a halt important progress in some
critical clinical situations.
This shortcoming and the variable response within European Member States to
the requirements of the Directive, prompted an expert meeting to be convened in
Vienna, Austria on 30 May 2005 (‘Vienna Initiative to save European Research’
[VISEAR]). A ﬁnal report was presented in December 2005 and full reports
appeared in the Wiener Klinische Wochenschrift in 2006. The initiative to the
meeting was supported by the Department for Ethics in Medical Research of the
Vienna Medical University, in cooperation with the European Forum for Good
Clinical Practice (EFGCP), the European Clinical Research Infrastructures Network
(ECRIN), and the Vienna School of Clinical Research. One of the six working
No Time to be Lost 373
123groups aimed at ‘clinical trials including patients who are not able to consent; the
concept of individual direct beneﬁt from research and informed consent in case of
the temporarily incapacitated patient’ Their recommendations were published in
2006 [6].
Consent Procedures
Informed consent in TBI victims can, due to the severity of the brain injury, never
be obtained from the patients. Proxies or an independent physician must give
consent for inclusion in research, or consent must be deferred or waived. Most
ethical committees in European countries consider consent by legal representatives
(proxy consent) valid. The moral basis for proxy consent is restricted to the
substituted judgment about the inclusion into the trial. The proxy is supposed to act
as the patient, if competent, would have decided. The question remains if the patient
wants to be represented by relatives for inclusion in a trial. Roupie et al. [22] found
that only 40.6% of 1,089 patients would want their spouse/partner to be their
surrogate, 28% want to be represented by the physician in charge of their care.
Coppolino and Ackerson [23] concluded that surrogate decision makers for
critical care research resulted in false-positive consent rates in up to 20%. In the
study by Sulmasy et al. [24], agreement between patients and proxies varied
between 57% and 81%, depending on whether previous discussions had taken place
on similar situations. It is very unlikely that such existential discussions occur
frequently in the target population prone to TBI (young adult males), resulting in
lack of evidence as to what their relative would have wanted in case of severe TBI.
Most proxies seem to make decisions in emergency situations based on what they
hope that will happen (survival of the patient), rather than what is likely to happen
(possible death or [severe] disability); this will bias decision-making towards
possible therapeutic beneﬁt, however small the chance will be [12].
In some European countries consent for randomization may be given by an
independent physician. Different perceptives on consent by a physician are reﬂected
in conﬂicting reports. In one study, 84% of patients with myocardial infarction felt
that the physician could independently decide on inclusion, if the patient was unable
to consent for himself [25]. In the ﬁeld of neonatology only 11% of parents believe
that physicians should decide regarding research participation [26].
With deferred (proxy) consent patients are included into the research without
prior consent. After inclusion, the patient (deferred consent) or his/her represen-
tatives (deferred proxy consent) should be informed as soon as possible and
subsequent informed consent should be requested.
With waiver of consent, all consent is waived. Emergency research without prior
consent (deferred consent or waiver of consent) can morally be accepted on the
principles of fairness, justice and beneﬁcence [27].
As severe TBI mostly occur outside the domestic situation (road trafﬁc
accidents), proxies are rarely available during the ﬁrst hours after TBI [28]. This
prompted investigators to use deferred (proxy) consent and waiver of consent in
emergency research facing very short therapeutic time windows. In the National
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of consent in a higher enrolment and reduced the time between injury and treatment
by approximately 45 min [27]. In this study, relatives of only 11 out of 113 patients
arrived within 6 h of the injury. In a septic shock trial the investigators could not
contact the proxies within the inclusion time in 74% of the cases, and these were
included under waiver of consent [19]. In the CRASH trial, mean time to
randomization was signiﬁcantly longer in those hospitals where consent was
required compared with those it was not (4.4 h [SE = 0.21] vs. 3.2 h [SE = 0.16]),
the difference in the mean time to randomization was 1.2 h [95% CI 0.7 to 1.8 h]
[29]. In our series in the dexanabinol trial only 174 out of 6,303 (2.7%) were
excluded for reason that proxy consent could not be obtained within 6 h after injury
[30].
Even when proxies are available, many do not know what the patient’s wishes are
[31]. Surrogate decision makers for critical-care research resulted in false-positive
consent rates of 16–20.3% [23]. The emotional nature of an emergency situation
limited the reliability of proxy consent for clinical research [26, 31, 32]. Only 48%
of 79 representatives of European Brain Injury Consortium (EBIC) associated
neuro-trauma centers in 19 European countries feel that relatives can make a
balanced decision in an emergency situation, 72% believed that a consent procedure
forms a signiﬁcant factor causing decrease in enrolment rate in a TBI study, and
83% believed that prior consent is a signiﬁcant factor causing delay in initiation of
study treatment [12]. Under emergency circumstances, proxy consent does not seem
to secure proper patient/subject protection. To our experience the validity of
informed consent and proxy consent given in an emergency situation is at least
troubling. When consent for clinical research is sought during an emergency
situation, comprehension is generally less than optimal [33–35]. A small minority
realized that pharmacological trials are designed to assess not only efﬁcacy but
safety as well [36]. One study searching for public views on emergency exception to
informed consent found that most (88%) of 530 people believed that research
subjects should be informed prior to being enrolled, while 49% believed enrolling
patients without prior consent in an emergency situation would be acceptable and
70% (369) would not object to being entered into such a study without providing
prospective informed consent [37]. In another study 11 of 12 stroke patients stated
that, if the patient of family was not able to consent, then the treating physician
should make the decision for inclusion in an emergency trial [38].
The requirement for all patients to give written informed (proxy) consent before
enrolment can result in major selection biases, such that registry patients were not
representative of the typical patient [39].
The Emergency Nature of Research in TBI
Traumatic Brain Injury is by deﬁnition an acute condition. The emergency nature of
pharmacological research in TBI is reﬂected by the fact that experimental and
clinical studies have shown that patho-physiological cascades are initiated within
minutes to hours following primary injury. Time windows for treatment modalities
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of many neuroprotective agents, if these were administered before, or within 15 min
after injury; others have shown a window of efﬁcacy of 3–6 h.
In the most recent international pharmacological trial in TBI, a phase III
randomized, placebo-controlled clinical trial investigating the efﬁcacy and safety of
a single dose Dexanabinol [40], the experimental data have consistently shown
better protection the sooner the agent is administered after TBI [41]. In the animal
model for TBI, this agent given up to 3 h after TBI was protective against
breakdown of the blood–brain barrier and reduced formation of edema and resulted
in less severe neurological symptoms [42]. Administered between 4 h and 6 h after
injury, no signiﬁcant reduction of cerebral edema was noticed, nevertheless
neurological symptoms improved. Based on these ﬁndings, it may be concluded that
in the experimental model the patho-physiologic endpoint can be determined at 3 h.
If this time window also form the clinical therapeutic border in patients with severe
TBI remains however uncertain. Time windows as applied to clinical trials in TBI
have rarely been based on experimental evidence, but were rather determined by
organizational and logistical considerations as to the time window within which
investigators expected that a considerable number of patients could be enrolled.
This was also the case in the recent Dexanabinol trial. One of the inclusion criteria
in this trial was ‘sustained TBI within the past 6 h [40] Informed consent could, seen
the severity of the brain injury, not be obtained from the patients. Proxy consent was
accepted in all participating countries. Deferred patient or proxy consent was only
allowed in Australia, Austria, Finland, France and Germany and consent by an
independent physician was allowed in Israel, Italy, Spain and the United Kingdom.
In all cases of deferred consent, subsequent written assent by patient or proxy was
obtained.
As coordinating quality control and assurance center for this trial, we had the
opportunity to study time windows in more detail [43]. We deﬁned for this analysis
four different time windows:
1. the time between injury and admission in a neuro-trauma center;
2. the time between admission in a neuro-trauma center and ﬁrst head CT scan;
3. the time between the ﬁrst head CT scan and proxy consent for inclusion in the
trial;
4. the time between proxy consent and study drug administration.
For analysis of these four time windows we selected 631 patients. The only
selection criterion was that the study drug was administered after written proxy
consent. Patients included in the trial under deferred consent were excluded from
our analysis. Furthermore, we only included patients from Europe and Israel,
excluding patients from Australia and the United States for other reasons [44]. The
time between injury and admission at the neuro-trauma center was for all selected
patients between 1 h, 16 h and 2.35 h (Table 1, Fig. 1). 501 (79.4%) patients were
directly admitted to the neuro-trauma center, 130 cases (20.6%) concerns secondary
referrals. In all patients the window between admission and the ﬁrst diagnostic CT
scan remains within 1 h. With exception of France, in all countries the median time
between injury and completion of the CT scan remained within the 3 h (Table 1).
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obtaining the required proxy consent (between 1.71 h and 2.74 h). The median time
between injury and obtained proxy consent was between 3.75 h and 5.00 h (IQR
2.75–5.38 h) (Table 1). After proxy consent was given, almost all patients
subsequently received the study drug within one hour (Table 1, Fig. 1). In 85.3%
of all cases the time between injury and study drug administration was longer than
4 h, in 60% of the cases even longer than 5 h.
Dexanabinol was one of the promising new pharmaceuticals in the treatment of
TBI, but it shown to be safe but not effective in the treatment of severe TBI [40].
Table 1 Time windows per country (median + IQR)
Country
(N)
Hours between
injury and
admission NTC
median (IQR)
Hours between
injury and CT scan
median (IQR)
Hours between injury
and obtained consent
median (IQR)
Hours between
injury and SDA
median (IQR)
Belgium (23) 0.93 (0.65–1.27) 1.80 (1.28–2.27) 3.75 (2.75–4.75) 4.60 (3.98–5.42)
Netherlands (73) 1.00 (0.75–1.33) 1.65 (1.32–2.00) 4.53 (3.95–5.05) 5.53 (5.07–5.75)
Israel (116) 0.93 (0.72–1.40) 1.91 (1.58–2.47) 4.01 (3.20–4.83) 4.67 (4.00–5.33)
Spain (75) 1.33 (0.97–1.67) 2.07 (1.65–2.53) 4.17 (3.33–5.00) 5.17 (4.30–5.58)
Germany (109) 1.20 (0.88–2.00) 1.65 (1.30–2.13) 4.08 (3.42–4.98) 5.25 (4.25–5.67)
Italy (146) 1.25 (0.83–2.60) 1.77 (1.40–2.35) 4.92 (4.08–5.28) 5.50 (4.98–5.75)
France (34) 2.17 (1.42–3.00) 3.08 (1.97–3.53) 5.00 (4.50–5.38) 5.75 (5.17–5.83)
Other countries*
(55)
1.47 (1.00–2.67) 1.82 (1.33–2.50) 4.00 (3.08–4.75) 5.25 (4.33–5.75)
*Countries with small patient populations (United Kingdom, Denmark, Austria, Poland, and Turkey)
were combined
belgium
netherlands
israel
spain
germany
italy
france
other
 injury           1h              2h              3h              4h              5h              6h 
time between injury and admission neurotrauma center time between admission and ct-scan
time between ct-scan and obtained consent time between consent and study drug admission
Fig. 1 Time between injury and admission neurotrauma center, time between admission and ﬁrst CT
scan, time between ﬁrst CT scan and informed consent for inclusion in trial and time between consent and
start study drug admission (from Ref. 43)
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provided earlier. Fact is that in almost all of the studied cases the time between
injury and completion of the primary diagnostic CT scan remains within 3 h post
injury, which is shown to be the therapeutic time window in the animal model. In
60% of the cases the time between injury and study drug administration was
however longer than 5 h, and in 85.3% of all cases longer than 4 h (Fig. 1). Our data
provide the empirical proof for considering deferred consent or waiver of consent in
trials with a very short therapeutic time window.
Risk-Beneﬁt Ratio
To my opinion the balance between risk and beneﬁt should be the guiding principle
in emergency research in severe TBI. This also applies to the nature and the type of
consent procedures. The ethical principle of respect for the autonomy of the patient
underpinning the informed consent procedures is not valid for acutely incapacitated
patients as TBI victims. Signiﬁcant concerns has been raised on the validity and
ethics of proxy consent in acute emergency situations, and the required written
consent cause a signiﬁcant delay in treatment initiation, as we have shown with our
analysis of the time windows. The possible therapeutic beneﬁt, as has been shown in
experimental models, form the moral justiﬁcation for randomizing patients under
deferred consent or waiver of consent within a sufﬁcient period of time. The risks
should however be acceptable in relation to the severity of the disease or injury. For
trials under deferred consent or waiver of consent in acute emergency situations we
would constrain the institution of an independent safety committee, under the
auspices of regulatory authorities. The obligation to such a committee is based on
the experience of a dramatically harmful outcome in some trials under waiver of
consent in other ﬁelds of medicine [45, 46].
Conclusions
Speciﬁc ethical issues pertaining in clinical testing of pharmacological neuropro-
tective agents in TBI include the emergency nature of the research, the incapacity of
the patients to informed consent before inclusion, short therapeutic time windows,
and a risk-beneﬁt ratio based on concept that in relation to the severity of the
trauma, signiﬁcant adverse side effects may be acceptable for treatments with
possible beneﬁt.
Time windows as applied to randomized controlled clinical trials in TBI have
rarely been based on experimental evidence, but were rather determined by
organizational and logistical considerations as to a time window within which
investigators expected that a considerable number of patients could be enrolled [12].
The main determinant is now formed by the informed (proxy) consent procedures,
as also has been compelled in the new European Union Directive 2001/20/EC [3, 6].
These requirements assume that relatives are available in emergency situations, and
that these relatives can be fully informed and given sufﬁcient time to make a
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for early initiation of experimental treatment versus the time required for following
consent procedures and the conﬂict between the desire for following consent
procedures requiring prior consent and the doubts about the validity of proxy
consent in acute situations are the most problematic aspects of emergency research
in TBI.
Clinical research in emergency situations without prospective informed or proxy
consent is ethically challenging. Severe TBI is without doubt an emergent and life-
threatening condition and existing therapy is unsatisfactory seen the high morbidity
and mortality in a mostly young group of patients. This should qualify severe TBI
for emergency exception form informed consent for randomized clinical controlled
trials with pharmacological agents with promising therapeutic beneﬁt facing short
therapeutic time windows. Randomized controlled investigations are necessary to
determine the safety and effectiveness of new developed agents in these conditions.
We have proved that the requirement of previous written proxy consent causes a
signiﬁcant delay till study drug administration in a trial with a neuroprotective agent
in TBI. With waiver of consent or deferred (proxy) consent the ﬁrst dose of the
experimental drug can be administered directly after completion of the ﬁrst
diagnostic CT scan, which is very close to the experimental therapeutic time
window. Randomized controlled phase III trials investigating the safety and efﬁcacy
of agents with promising beneﬁt, conducted in acute emergency situations with
short therapeutic time windows, should allow randomization under deferred (proxy)
consent or waiver of consent. Making progress in knowledge of treatment in acute
neurological and other intensive care conditions is only possible if national
regulations and legislations allow waiver of consent or deferred (proxy) consent for
clinical trials [15]. As two of us have said before: ‘treat ﬁrst, ask later’ seems
ethically defendable in acute care research [4].
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